These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 39223552

  • 21. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
    Shamu T, Egger M, Mudzviti T, Chimbetete C, Manasa J, Anderegg N.
    PLoS One; 2024; 19(2):e0293162. PubMed ID: 38394297
    [Abstract] [Full Text] [Related]

  • 22. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS, Dokubo EK, Sint TT.
    Cochrane Database Syst Rev; 2010 Mar 17; (3):CD008440. PubMed ID: 20238370
    [Abstract] [Full Text] [Related]

  • 23. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz.
    Asif S, Baxevanidi E, Hill A, Venter WDF, Fairlie L, Masenya M, Serenata C, Sokhela S, Chandiwana N.
    AIDS; 2021 Dec 15; 35(Suppl 2):S117-S125. PubMed ID: 34261099
    [Abstract] [Full Text] [Related]

  • 24. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
    Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, Myer L, Waitt C, Reynolds H, Khoo S.
    AIDS Res Ther; 2022 Jun 07; 19(1):24. PubMed ID: 35672853
    [Abstract] [Full Text] [Related]

  • 25. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S, Vitoria M, Doherty M, Socias ME, Ford N, Forrest JI, Popoff E, Bansback N, Nsanzimana S, Thorlund K, Mills EJ.
    Lancet HIV; 2016 Nov 07; 3(11):e510-e520. PubMed ID: 27658869
    [Abstract] [Full Text] [Related]

  • 26. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC, Morrison RL, Shapiro DE, Chakhtoura N, Gouvèa MIS, de Lourdes B Teixeira M, Fuller TL, Mmbaga BT, Ngocho JS, Njau BN, Violari A, Mathiba R, Essack Z, Pilotto JHS, Moreira LF, Rolon MJ, Cahn P, Prommas S, Cressey TR, Chokephaibulkit K, Werarak P, Laimon L, Hennessy R, Frenkel LM, Anthony P, Best BM, Siberry GK, Mirochnick M.
    Lancet HIV; 2020 May 07; 7(5):e322-e331. PubMed ID: 32386720
    [Abstract] [Full Text] [Related]

  • 27. An observational cohort study to investigate the impact of dolutegravir in pregnancy and its obesogenic effects on the metabolic health of women living with HIV and their children: Study protocol.
    Abrams EJ, Jao J, Madlala HP, Zerbe A, Catalano P, Gerschenson M, Goedecke JH, Gomba Y, Josefson J, Kurland IJ, Legbedze J, McComsey GA, Matyesini S, Mukonda E, Robinson D, Myer L.
    PLoS One; 2024 May 07; 19(8):e0307296. PubMed ID: 39159183
    [Abstract] [Full Text] [Related]

  • 28. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
    Mmasa KN, Powis K, Sun S, Makhema J, Mmalane M, Kgole S, Masasa G, Moyo S, Gerschenson M, Mohammed T, Legbedze J, Abrams EJ, Kurland IJ, Geffner ME, Jao J.
    HIV Med; 2021 Sep 07; 22(8):715-722. PubMed ID: 34003565
    [Abstract] [Full Text] [Related]

  • 29. Congenital anomalies following antenatal exposure to dolutegravir: a Canadian surveillance study.
    Money D, Lee T, O'Brien C, Brophy J, Bitnun A, Kakkar F, Boucoiran I, Alimenti A, Vaudry W, Singer J, Sauve LJ, Canadian Perinatal HIV Surveillance Program.
    BJOG; 2019 Oct 07; 126(11):1338-1345. PubMed ID: 31188522
    [Abstract] [Full Text] [Related]

  • 30. Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.
    Bishop MD, Korutaro V, Boyce CL, Beck IA, Styrchak SM, Knowles K, Ziemba L, Brummel SS, Coletti A, Jean-Philippe P, Chakhtoura N, Vhembo T, Cassim H, Owor M, Fairlie L, Moyo S, Chinula L, Lockman S, Frenkel LM.
    J Acquir Immune Defic Syndr; 2024 Aug 07; 96(4):385-392. PubMed ID: 39175843
    [Abstract] [Full Text] [Related]

  • 31. Clinical Trials That Have Changed Clinical Practice and Care of Pregnant People With HIV.
    Fisher SA, Madden N, Espinal M, Garcia PM, Jao JK, Yee LM.
    Clin Obstet Gynecol; 2024 Jun 01; 67(2):381-398. PubMed ID: 38450526
    [Abstract] [Full Text] [Related]

  • 32. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saϊdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D, ODYSSEY Trial Team.
    BMC Infect Dis; 2021 Jan 04; 21(1):5. PubMed ID: 33446115
    [Abstract] [Full Text] [Related]

  • 33. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N, McCann K, Norris S, Chersich M, Maartens G, Lalla-Edward S, Vos A, Clayden P, Abrams E, Arulappan N, Hill A.
    Lancet HIV; 2020 Oct 04; 7(10):e666-e676. PubMed ID: 33010240
    [Abstract] [Full Text] [Related]

  • 34. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
    Zash R, Souda S, Chen JY, Binda K, Dryden-Peterson S, Lockman S, Mmalane M, Makhema J, Essex M, Shapiro R.
    J Acquir Immune Defic Syndr; 2016 Apr 01; 71(4):428-36. PubMed ID: 26379069
    [Abstract] [Full Text] [Related]

  • 35. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, Yee LM, Chadwick EG, Shiau S, Jacobson DL, Brummel SS, Sultan-Beyer L, Kahlert CR, Zash R, Seage GR, Pediatric HIV/AIDS Cohort Study, Swiss Mother and Child HIV Cohort Study.
    N Engl J Med; 2022 Sep 01; 387(9):799-809. PubMed ID: 36053505
    [Abstract] [Full Text] [Related]

  • 36. Clinical, pharmacological, and qualitative characterization of drug-drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa.
    Kiiza D, Rostami-Hochaghan D, Alhassan Y, Seden K, Reynolds H, Kaboggoza JP, Taegtmeyer M, Chen T, Challenger E, Malaba T, Wang D, Else L, Hern F, Sharp J, Neary M, Dilly Penchala S, Waitt C, Orrell C, Colbers A, Myer L, Owen A, Rannard S, Khoo S, Lamorde M.
    J Antimicrob Chemother; 2024 Sep 03; 79(9):2334-2342. PubMed ID: 38997229
    [Abstract] [Full Text] [Related]

  • 37. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
    van der Wekken-Pas L, Nassiwa S, Malaba T, Lamorde M, Myer L, Waitt C, Reynolds H, Khoo S, He N, van Leeuwen L, Burger D, Wang D, Colbers A.
    AIDS; 2024 Jun 01; 38(7):975-981. PubMed ID: 38277390
    [Abstract] [Full Text] [Related]

  • 38. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A, Icona Foundation Study Group.
    J Int AIDS Soc; 2019 Jan 01; 22(1):e25227. PubMed ID: 30663278
    [Abstract] [Full Text] [Related]

  • 39. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA, Miller S, Childs-Kean LM.
    Ann Pharmacother; 2020 Dec 01; 54(12):1252-1259. PubMed ID: 32517480
    [Abstract] [Full Text] [Related]

  • 40. Switch to dolutegravir is well tolerated in Thais with HIV infection.
    Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, Chomchey N, Kanaprach R, Prueksakaew P, Suttichom D, Trichavaroj R, Spudich S, Robb ML, Phanuphak P, Phanuphak N, Ananworanich J, RV254/SEARCH 010 Study Group.
    J Int AIDS Soc; 2019 Jul 01; 22(7):e25324. PubMed ID: 31294931
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.